The effects of ecstasy on neurotransmitter systems: a review on the findings of molecular imaging studies by unknown
REVIEW
The effects of ecstasy on neurotransmitter systems: a review
on the findings of molecular imaging studies
Yosta Vegting1 & Liesbeth Reneman2,3 & Jan Booij1,3
Received: 28 January 2016 /Accepted: 20 July 2016 /Published online: 28 August 2016
# The Author(s) 2016. This article is published with open access at Springerlink.com
Abstract
Rationale Ecstasy is a commonly used psychoactive drug
with 3,4-methylenedioxymethamphetamine (MDMA) as the
main content. Importantly, it has been suggested that use of
MDMA may be neurotoxic particularly for serotonergic (5-
hydroxytryptamine (5-HT)) neurons. In the past decades, sev-
eral molecular imaging studies examined directly in vivo the
effects of ecstasy/MDMA on neurotransmitter systems.
Objectives The objective of the present study is to review the
effects of ecstasy/MDMA on neurotransmitter systems as
assessed by molecular imaging studies in small animals,
non-human primates and humans.
Methods A search in PubMed was performed. Eighty-eight
articles were found on which inclusion and exclusion criteria
were applied.
Results Thirty-three studies met the inclusion criteria; all were
focused on the 5-HTor dopamine (DA) system. Importantly, 9
out of 11 of the animal studies that examined the effects of
MDMA on 5-HT transporter (SERT) availability showed a
significant loss of binding potential. In human studies, this
was the case for 14 out of 16 studies, particularly in heavy
users. In abstinent users, significant recovery of SERT binding
was found over time. Most imaging studies in humans that
focused on the DA system did not find any significant effect of
ecstasy/MDMA use.
Conclusions Preclinical and clinical molecular imaging stud-
ies on the effects of ecstasy/MDMA use/administration on
neurotransmitter systems show quite consistent alterations of
the 5-HT system. Particularly, in human studies, loss of SERT
binding was observed in heavy ecstasy users, which might
reflect 5-HT neurotoxicity, although alternative explanations
(e.g. down-regulation of the SERT) cannot be excluded.
Keywords 3,4-Methylenedioxymethamphetamine .
MDMA . Ecstasy . Neuroimaging . PET . SPECT . fMRI .
Neurotoxicity . Serotonin . Dopamine
Introduction
Ecstasy is a common recreationally used psychoactive drug. The
name ecstasy refers to the main effects of the drug, because the
Greek word Bεκστασις^ (ekstasis) means Bstanding out of
yourself^. Euphoric feelings and the ability to socialize can be
increased after use of ecstasy/3,4-methylenedioxy-
methamphetamine (MDMA). Moreover, people can experience
entactogenic effects and feel extremely connected with others
and some even have mild hallucinations (Reynolds 2013).
These effects are caused byMDMA, the main content of ecstasy
tablets, through a mechanism of enhanced release of the neuro-
transmitter serotonin (5-hydroxytryptamine (5-HT)) as well as a
relatively small release of anothermonoaminergic neurotransmit-
ter, namely dopamine (2-(3,4-dihydroxyfenyl)-ethaanamine
(DA)) (Lyles and Cadet 2003). Although it is well known from
animal studies that MDMA administration induces a massive
release of 5-HT and that frequent administrations of MDMA
may induce neurotoxic effects on the 5-HT system (Commins
et al. 1987; Lyles and Cadet 2003), administration of MDMA
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may also induce changes on other neurotransmitter systems.
Indeed, Battaglia et al. (1988) showed that MDMA has non-
negligible affinity for not only 5-HT1 and 5-HT2 receptors, but
also α1-adrenergic receptors, α2-adrenergic receptors, β-
adrenergic receptors, muscarinicM1 andM2 receptors, histamine
H1 receptors, DA D1 and D2 receptors, opioid receptors and
benzodiazepine receptor sites.
With the use of molecular neuroimaging techniques like
single-photon emission computed tomography (SPECT) and
positron emission tomography (PET) imaging, neurotransmit-
ter systems in the living brain can be visualized and specific
receptors/transporters quantified, both in laboratory animals,
in non-human primates and in humans. Several human molec-
ular imaging studies indicated that the 5-HT transporter
(SERT) binding is decreased in different brain regions of fre-
quent MDMA users (Buchert et al. 2007; McCann et al. 2005;
Zhou et al. 1998). However, there is discussion whether this
alteration in binding may reflect neurotoxicity. Some experi-
mental studies in rodents and primates indicate that adminis-
tration of MDMA damages the structural and functional in-
tegrity of the 5-HT system. In these studies, immunocyto-
chemistry was used and markers of 5-HT axon degeneration
were assessed, e.g. concentrations of 5-hydroxyindoleacetic
acid (5-HIAA), 5-HT and the SERT (Battaglia et al. 1987;
Commins et al. 1987). Immunocytochemistry showed mor-
phologic evidence of neuronal degeneration due to adminis-
tration of MDMA (Battaglia et al. 1987; Molliver et al. 1990;
O’Hearn et al. 1988; Ricaurte and McCann 1992). In contrast,
alternative explanations for the loss of SERT after MDMA
administration were put forward as well. It was suggested that
the administration of MDMA may cause a state of metabolic
exhaustion through a mechanism of modifications in gene
expression and protein function (Baumann et al. 2007). This
hypothesis is supported by studies that measured glial activa-
tion and silver staining, also indicators of neurotoxicity. In
these studies, no correlation was found between 5-HT deple-
tion induced by MDMA administration and markers of neu-
rotoxicity in mice treated with 10–20 mg/kg MDMA (Pubill
et al. 2003; Wang et al. 2004).
The United Nations Office on Drugs and Crime has esti-
mated that there were 18.8 million ecstasy users worldwide in
2013. From 2009 to 2013, a decrease was found in the prev-
alence of ecstasy use in the past year in subjects of 15 to
64 years (United Nations Office on Drugs and Crime 2015).
However, the average amount of MDMA in an ecstasy tablet
in the Netherlands has increased over the years (Van Laar et al.
2015; Vogels et al. 2009). Therefore, the amount of MDMA
administered within a short time frame may have risen.
Although in the last 10 years, the average dosage of
MDMA in ecstasy tablets has increased, potential long-term
effects of MDMA/ecstasy use remain unclear, most likely be-
cause the conducted studies differ in their methodology and
findings are thus difficult to compare. It has been suggested
that ecstasy use might be a threat for public health (Cowan
2007); however, at the same time, an increased interest in the
use of MDMA in a therapeutic setting is being reported, for
example, to enhance the effectiveness of psychotherapy in
resistant, chronic posttraumatic stress disorder (PTSD)
(Oehen et al. 2013). Also, a recently published review of
Mueller et al. (2015) did not find convincing evidence from
neuroimaging studies that moderate use of MDMA is neuro-
toxic in humans.
To draw conclusions whether MDMAmay induce changes
in neurotransmitter systems, we offer a review of the results of
imaging studies on the effects of ecstasy/MDMA on neuro-
transmitter systems in small laboratory animals, non-human
primates and humans.
Methodology
Search and information source
With the search terms stated below (Table 1), a search in the
online database PubMed was carried out updated until 14
November 2015. The Patient–Intervention–Comparison–
Outcomes (PICO) system (Richardson et al. 1995) was used
to construct the search. To increase the sensitivity of the
search, finally, only search terms for the intervention with
MDMA and search terms for the different imaging techniques
were included.
Selection of studies
Full-text articles were obtained on which inclusion and exclu-
sion criteria were applied. Criteria for selecting the articles
were as follows. Publications were included if (1) in vivo
imaging findings on neurotransmitter systems were reported
and (2) the data was obtained in a control group with an
MDMA-naive condition or in a serial measurement in which
the baseline measurement (T1) was in a MDMA-naive state.
Publications were excluded if (1) the study design was a case
report study or a review, (2) MDMA was given as a single
challenge, or (3) the study was a re-evaluation of previously
Table 1 Search terms in PubMed
((BN-Methyl-3,4-methylenedioxyamphetamine^[Mesh] OR
MDMA[tiab] OR Ecstasy[tiab] OR Ecstacy[tiab] OR
methylenedioxyamphetamine[tiab] OR N 3,4
Methylenedioxyamphetamine[tiab]) OR Ecstacy*)) AND
(BTomography, Emission-Computed, Single-Photon^[Mesh] OR
SPECT[tiab] OR PET[tiab] OR PET scan* OR SPECT scan* OR
Single-Photon Emission-Computed Tomograph* OR BPositron-
Emission Tomography^[Mesh] OR Positron-Emission Tomograph*
OR phMRI[tiab] OR pharmacological MRI[tiab])
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published data. Figure 1 shows the flowchart of the inclusion
and exclusion of the studies.
Data extraction
Data was extracted about the (1) receptor/transporter studied,
(2) number of participated subjects and controls with key fea-
tures, (3) radiotracer used, (4) amount of ecstasy use/adminis-
tration, (5) minimal time of MDMA/ecstasy abstinence and
(6) results of the particular study. We extracted and reported P
values and preferablyP values that were corrected for multiple
comparisons. For the papers that reported means and standard
deviations, we calculated the percentage of alteration of tracer
binding. We defined an increase or reduction as follows:
Alteration ¼ 100* imaging outcome measure in MDMA users−outcome measure in controlsð Þoutcome measure in controls
and expressed it as a percentage. To estimate the size of the
differences found (between the MDMA group and the control
condition), we calculated effect sizes (ES), using the Cohen’s
d. We subtracted the mean of the control group from the mean
of the MDMA group, which was divided by the pooled stan-
dard deviation as follows: d ¼ M MDMA−M controlSD pooled .
Results
Inclusion of studies
Eighty-eight studies were found after the initial search in
PubMed (Fig. 1). Thirty-three studies were included after ap-
plying inclusion and exclusion criteria as mentioned before.
The included studies examined the effects of ecstasy on 5-HT
synthesis, the SERT, 5-HT2A receptor, 5-HT1A receptor, 5-
HT-ergic vesicular monoamine transporter (VMAT; i.e.
VMATexpression in 5-HT-rich brain areas), DAD2/3 receptor
and DA release, the DA transporter (DAT), decarboxylase




In our search, only one human study on 5-HT synthesis was
found and included (Table 2). A whole-brain SPM analysis
showed decreased 5-HT synthesis in a large brain area, from
the prefrontal and orbitofrontal cortex all the way up to the
posterior parietal cortex in MDMA polydrug users compared
to polydrug using controls (data not in Table 2). Also, increased
uptake was observed in the brainstem, in the region of the
periaqueductal grey matter, as well as in parts of the left lateral
prefrontal cortex and temporal cortex. The volumes of interest
(VOI) analyses, in which gender effects were assessed, showed
that 5-HT synthesis levels were significantly increased in the
raphe nuclei (raphe, P = 0.01, effect size (ES) = 1.43) and tend
to be increased in the brainstem in female MDMA polydrug
users compared to female controls (Table 2). Furthermore, a
significant decreased tracer uptake was found in the lateral
orbitofrontal brain area in female MDMA polydrug users as
compared to female controls. Male MDMA polydrug users
showed lower uptake in the pre-central gyrus compared to male
controls (pre-central gyrus, P = 0.029, ES = −1.14).
Serotonin transporter
Twenty-seven studies were included that studied SERT bind-
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Fig. 1 Flowchart of the inclusion
and exclusion of studies
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animals and 16 studies in humans. Importantly, 14 out of 16 of
the human studies showed a significant loss of SERT binding,
while in animal studies, this was found in 9 out of 11 studies.
All over, the ES were larger (ranging from −0.38 to −20.03) in
animal studies than in human studies (ranging from −0.05 to
−2.17).
5-HT2A receptor
As shown in Table 5, only five human studies examined
in vivo the effects of MDMA on 5-HT2A receptor binding.
A couple of animal studies explored the effects of ecstasy
administration on the 5-HT2A receptor as well; however, those
studies were excluded because they only used ex vivo imaging
techniques. Out of these five human studies, three showed a
significant increase in 5-HT2A receptor binding in MDMA
users compared to controls. In contrast, the other two studies
showed a significant decrease of binding.
5-HT1A receptor
In this review, we found one animal study on the 5-HT1A
receptor, which could be included. As can be seen from the
data presented in Table 6, no significant differences in 5-HT1A
receptor binding were found between the baseline scan and
the scan after MDMA treatment.
Serotonergic vesicular monoamine transporter
The vesicular monoamine transporter (VMAT) is expressed in
all monoaminergic neurons. However, in 5-HT-rich brain
areas, such as the hypothalamus, VMATexpression represents
preferentially VMAT expression in 5-HT neurons. Solely,
Fantegrossi et al. (2004) studied VMAT binding in 5-HT-
rich parts of the brain (midline structures consisting of thalam-
ic and hypothalamic nuclei) as is shown in Table 7. Seven
monkeys were studied, whereof four monkeys self-
administered MDMA. No significant differences in VMAT
binding were reported between both two groups.
Dopamine system
Dopamine D2/3 receptor and dopamine release
One study was included that explored the effect of MDMA on
striatal DA D2/3 receptors and endogenous DA release
(Table 8). At baseline level, striatal D2/3 binding was lower
in ex-MDMA users than controls, in all subdivisions of the
striatum, although this result was not statistically significant.
After playing a video game, ex-MDMA users seemed to have
a lower DA release in both left and right caudate nucleus and
putamen than controls. However, none of these differences
were statistically significant and ES were relatively low rang-
ing from 0.07 to 0.32.
Table 2 5-HT synthesis human studies
Technique
used
Author Nr pts/controls Inclusion and
exclusion criteria
MDMA check Outcome Effect
size












Raphe: increase 3 % 0.10
Use of other drugs
allowed
Brainstem: increase 6 % 0.86










Raphe: increase (P = 0.01) 30 % 1.43
Brainstem: increase 9 % 0.58
Pre-cuneus: decrease −1 % −0.07
Pre-central gyrus: increase 0 % 0.03
Lateral orbitofrontal:
decrease (P = 0.03)
−11 % −1.14
This table shows the results of human studies on 5-HT synthesis (VOI analyses; data taken from Table 5 in Booij et al. 2014, since these data could be
used to calculate effect sizes). Only significant P values (not corrected for multiple comparisons) are presented. BMDMA^ means MDMA users. BPD-
Controls^ are polydrug users (excluding MDMA use)
a Results are shown of a selection of brain regions
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Dopamine transporter
Three studies were found and included that examined the DAT
in ecstasy users (Table 9). One study showed a significant
increase of 13 % in striatal binding ratios of MDMA users
compared to controls (striatal binding ratios, P = 0.045,
ES = 2.92), whereas the other two studies did not show any
significant difference.
Decarboxylase activity ([18F]dopa positron emission
tomography)
Table 10 presents data of one study that was included exam-
ining decarboxylase activity. This research indicated that de-
carboxylase activity was increased in the caudate nucleus,
putamen (putamen, P = 0.021, ES = 1.10) and ventral striatum
comparing ex-MDMA users to drug-naive controls. ES
ranged from 0.52 to 1.10. Ex-MDMA users were also com-
pared to polydrug using controls, but this comparison showed
no significant effect anymore (ES ranged from −0.04 to 0.47).
Vesicular monoamine transporter-dopaminergic
In this review, one animal study was found that investigated
the VMAT in a DA-ergic brain area (basal ganglia) (Table 11).
No significant differences were found in distribution volume
ratios comparing MDMA self-administering monkeys to
drug-naive controls.
Discussion
Results of molecular imaging studies showed quite consistent-
ly that SERT binding is lower after use/administration of ec-
stasy/MDMA, particularly after administration of high dos-
ages, while studies on the 5-HT2A receptor showed inconsis-
tent results. Results of molecular imaging studies on the DA
system are quite consistent in that most molecular imaging
studies in humans did not find any significant effect of
MDMA on the dopamine system. Here, we will focus primar-
ily on the statistically significant findings reported in Tables 2,
3, 4, 5, 6, 7, 8, 9, 10 and 11.
5-Hydroxytryptamine synthesis
In this review, only one human study on 5-HT synthesis was
included (Table 2). Themain reason that, until recently, only one
study looked into 5-HT synthesis in MDMA users is that the
PET radiotracer, alpha-[11C]-methyl-l-tryptophan ([11C]AMT),
which is a well-validated radiotracer to measure 5-HTsynthesis,
is hardly available. In this study, only 17 MDMA users and 18
age-matched controls were included, whereof half of the
MDMA users and controls were men. Increases and decreases
Table 6 5-HT1A receptor animal studies









No consistent or significant effect
of MDMA treatment on [11C]
WAY-100635 in any brain region
a
This table shows the results of the animal studies included into the 5-HT1A receptor. Only significant P values (not corrected for multiple comparisons)
are presented. BBaseline + MDMA^ means that a baseline scan was taken, followed by that MDMAwas given and a second scan was taken
a Not all results were shown in the publication; therefore, the effect sizes could not be calculated
Table 7 5-HT-ergic vesicular monoamine transporter (VMAT) animal studies
Technique used Author Nr pts/
controls















DVR midline structures (thalamic
and hypothalamic nuclei) vs
occipital cortex: no significant
differencesa
b
This table reports the results of the animal studies included on 5-HT-ergic VMAT. BSA-MDMA^ is monkeys that self-administered MDMA. BPD-
Controls^ are polydrug controls (excluding MDMA self-administration). BDVR^ is the distribution volume ratio of [11 C]DTBZ
aAlso presented in Table 11: DA-ergic VMAT
bNot all results were shown in the paper; therefore, the effect sizes could not be calculated
Psychopharmacology (2016) 233:3473–3501 3491
in [11C]AMT trapping were observed comparing MDMA users
with controls; however, decreases were mainly seen in prefron-
tal–orbital and parietal regions and increases in the brainstem.
The differences were more extensive in men than in women. As
suggested by the authors, the decreases in the forebrain may
reflect 5-HT neurotoxicity and the increases in the brainstem
could be explained by an up-regulation of synthesis to compen-
sate the loss of 5-HT neurons. Nevertheless, further research
should be performed to draw definitive conclusions whether 5-
HTsynthesis is altered inMDMAusers. Also, it may be relevant
to perform studies in small laboratory animals with this radio-
tracer, to validate whether administration of MDMA is able to
induce detectable changes in 5-HT synthesis as assessed by this
radiotracer and to study the relationship between 5-HTsynthesis
and 5-HT neurotoxicity.
Serotonin transporter
Eleven animal studies looked into the effects of MDMA on
SERT binding, and all of them showed lower SERT binding,
reaching statistical significant effects in ten of these studies
(Table 3). The ES were large (ranging from −0.38 to −20.03),
which indicates that the effect of MDMA on SERT binding is
a robust finding in animals. As compared to human studies, an
advantage of animal studies is that the animals were solely
treated with MDMA. In humans, however, polydrug use is
common, which makes it harder to look at the effects of
MDMA per se (Gouzoulis-Mayfrank and Daumann 2006).
Consequently, it may be hard to generalize the findings
observed in animals to humans. Also, in animal studies,
MDMAwas administered frequently. Indeed, most of the an-
imal studies administered MDMA twice a day for 4 days in a
row, whereas humans typically only use one or two tablets of
ecstasy in the weekend. Moreover, relatively high doses with-
in a short interval (e.g. two doses per day for four consecutive
days) of MDMAwere used in the animal studies (range 20–
141 mg/kg), which may explain the large ES, and the drug
was administered commonly intraperitoneally. However,
some research indicates that due to differences in metabolism,
neurotoxic dosages of MDMA are different between small
animal species and primates. In rats, only high dosages of at
least 20 mg/kg may be neurotoxic (Schmidt 1987). Using
differences in clearance and body mass/surface area between
monkeys and humans, an estimation of the neurotoxic dosage
of MDMA for a human can be made, which was estimated at
1.28 mg/kg by Ricaurte et al. (2000). As mentioned before,
humans typically use one or two tablets of ecstasy, each con-
taining approximately 138 mg (reflecting 2–4 mg/kg in a per-
son of 70 kg) (Van Laar et al. 2015). This dosagemay be in the
neurotoxic range based on the prediction by Ricaurte et al.
(2000). In contrast, Baumann et al. (2007) argued that inter-
species scaling, which means adjusting doses between spe-
cies, should not be used, because behavioural, endocrine and
neurochemical reactions will occur at corresponding doses,
around 1–2 mg/kg. Furthermore, other researchers argued that
high doses, i.e. >25 mg/kg, of MDMA produce neurotoxicity
to all types of neurons (Jensen et al. 1993). These findings
implicate that the doses of MDMA used in most animal
Table 8 DA D2/3 + DA release human studies















Use of other drugs
PD-Controls: no current or
recent use





After videogame vs baseline:
Left caudate: decrease −6 % 0.07
Right caudate: decrease −3 % 0.07
Left putamen: decrease −1 % 0.10
Right putamen: decrease 1 % 0.10
PD-Controls:b
After videogame vs baseline:




Left putamen: decrease −7 % 0.29
Right putamen: decrease −9 % 0.32
Baseline:
Ex-MDMA vs PD-Controls:
Left caudate: decrease −17 % −0.41
Right caudate: decrease −19 % −0.50
Left putamen: decrease −16 % −0.44
Right putamen: decrease −17 % −0.53
This table shows the results of human studies into DA D2/3 + DA release. Only significant P values (not corrected for multiple comparisons) are
presented. BEx-MDMA^ is former MDMA users. BPD-Controls^ are polydrug controls (excluding MDMA use)
a Included patients that used antipsychotic treatment; however, they did not take their medication for 6 months at the time of the scans. There was no
formal urine screening test to check the reported abstinence of drugs
bMore longitudinal data not shown in the table
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research might be too high to compare the results of these
studies with human studies.
Consistent with findings in animals, 14 out of the 16
SERT studies performed in humans also showed signifi-
cantly lower SERT binding, particularly in cortical brain
areas. However, not all studies corrected for multiple
comparisons. Ten studies examined SERT binding in the
occipital cortex, and in six of these studies, the decrease
of SERT binding was most pronounced in this particular
brain area, with ES ranging from −0.21 to −2.17. Several
experimental studies have reported that, indeed, high
doses of ecstasy affect preferentially 5-HT-ergic projec-
tions to the occipital cortex (Oliveri and Calvo 2003).
Hadzidimitrou and colleagues (1999) and Molliver et al.
(1990) stated that axons with a great length, e.g. axons to
the occipital cortex, have a higher sensitivity to neurotox-
ic substances. Besides the cortical regions, forebrain re-
gions were also examined. Four studies explored hippo-
campal SERT, and in 3 out of these 4 studies was the
SERT binding significantly reduced in MDMA users;
however, only 2 were corrected for multiple comparisons.
It has been shown that heavy MDMA users have verbal
and visuo-spatial memory deficits, and loss of SERT in
the hippocampus may contribute to these deficits (Bosch
et al. 2013). For cognitive processes like language and
memory, the thalamus is also very important (Herrero
et al. 2002). Eleven studies found that the SERT binding
was lower in this brain area in users with a history of
ecstasy use; however, only three studies showed signifi-
cant effects. It might be that SERT loss in the thalamus
plays a key role in verbal memory deficits too.
The study of Urban et al. (2012) showed statistically non-
significant decreases of −100 % in SERT binding in the
orbitofrontal and parietal cortex. These large percentages can
be explained by the fact that the binding of [¹¹C]DASB in
these regions is very low, which hampers an accurate quanti-
fication of SERT binding.
It should be considered that different radiotracers with dif-
ferent binding characteristics were used in studies on the ef-
fects ofMDMAuse/administration on SERT, which may have
influenced outcomes. SPECT studies used the non-selective
tracer [123I]β-CIT, while PET studies used selective tracers,
e.g. [11C]DASB and [18F]ADAM (Chen et al. 2012; Frankle
et al. 2004). Since [123I]β-CIT binds with high affinity to both
the DAT and SERT, SERT binding in DAT-rich areas (i.e.
striatum) cannot be assessed with this radiotracer. Other meth-
odological issues could have affected the accuracy of the
quantitative measurements as well. For example, simple ratio
methods were used in the SERT SPECT studies, which are
more prone to changes in tracer delivery, whereas modelling
time activity curves were used in some PET studies (e.g. the
study of Booij et al. (2014)). Finally, the limited spatial reso-
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scanners, can lead to an underestimation of the binding poten-
tial in small volumes (partial volume effect) (Erlandsson et al.
2012).
In the past 10 years, another technique called pharmaco-
logical MRI was evaluated to assess 5-HT dysfunction. This
technique measures the hemodynamic response on a pharma-
ceutical, e.g. a selective serotonin reuptake inhibitor (SSRI). It
is a very interesting development; however, more research is
necessary to validate this technique (Schouw et al. 2012;
Wingen et al. 2008).
Although the results of the included studies may be influ-
enced by differences in tracer and techniques (PET versus
SPECT, but also analysis techniques), the findings of imaging
studies on SERT were robust. Confirming previous studies,
use/administration of MDMA declines SERT binding.
5-HT2A receptor
Three out of five imaging studies showed an increased 5-
HT2A binding in MDMA users (Table 5). In these three stud-
ies, the period of abstinence for ecstasy ranged between 2.0
and 169.8 weeks and ES ranged between 0.14 and 1.84. The
other two studies showed a loss of 5-HT2A receptor binding,
and in these studies, the period of abstinence ranged between
1.6 and 36.9 weeks. The [123I]R91150 SPECT study of
Reneman et al. (2002c) showed that in recent MDMA users
(mean time of abstinence 3.3 weeks), postsynaptic 5-HT2A
receptor binding was significantly lower in all cortical areas
studied, while 5-HT2A receptor densities were significantly
higher in the occipital cortex of ex-MDMA users. Moreover,
this study showed a significant positive correlation between
cortical 5-HT2A receptor binding and duration of abstinence
from MDMA (P < 0.01). Also, the same study showed, using
an ex vivo technique in rats and using the same radiotracer, a
decrease of binding followed by a time-dependent recovery of
cortical 5-HT2A receptor binding, which was strongly and
positively associated with the degree of 5-HT depletion
(Reneman et al. 2002c). However, no positive correlation be-
tween the 5-HT2A receptor binding and time of abstinencewas
found in the other studies (Di Iorio et al. 2012; Erritzoe et al.
2011; Urban et al. 2012). The time of abstinence in the study
of Erritzoe et al. (2011) ranged between 1.6 and 36.9 weeks
and in the study of Di Iorio et al. (2012) between 34 and
169.8 weeks, so these ranges should be large enough to eval-
uate a possible correlation between 5-HT2A receptor binding
and time of abstinence. Moreover, the study of Urban et al.
(2012) did not show a decrease in receptor binding, although
the subjects were also relatively recent MDMA users (mean
time of abstinence 5.7 weeks, ranging from 2 to 8 weeks),
comparable to the study of Reneman et al. (2002c). So, all in
all, findings on 5-HT2A receptor binding in MDMA users are
inconsistent and it is uncertain if there is a relationship be-
tween time of abstinence and 5-HT2A receptor binding.
Dopamine system (dopaminergic vesicular monoamine
transporter, D2/3 receptor and dopamine release,
dopamine transporter, decarboxylase activity)
Some experimental studies in animals suggested that admin-
istration of MDMA/ecstasy affects not only the 5-HT system,
but also the DA system. For example, Commins et al. (1987)
showed that when MDMAwas given to rats in a high dosage,
DA levels were decreased in some brain regions. However,
other research showed that treatment withMDMA/ecstasy has
limited effect on the dopamine nerve endings in rats (Battaglia
et al. 1987; Stone et al. 1986). In mice, MDMA seems to be a
selective DA neurotoxin, while in rats a selective 5-HT neu-
rotoxin (Stone et al. 1986). Therefore, Easton and Marsden
questioned the ability to translate findings of animal studies on
DA neurotoxicity to humans (Easton and Marsden 2006).
In this search, we found one animal study and five human
imaging studies that examined the influence of ecstasy on the
central DA system and they showed consistently no signifi-
cant effects of MDMA on the DA system (Tables 8, 9, 10 and
11). One study inmonkeys examined the VMATexpression in
the basal ganglia but did not find significant differences be-
tween the self-administeringMDMA group and the polydrug-
administering control group. One human study explored the
effect of MDMA on baseline DA D2/3 receptors and DA
release and no significant differences were found. Three
studies examined striatal DAT binding in MDMA users;
however, only one study of Reneman et al. (2002b) showed
statistically significant differences. In that particular study, the
effects of use of MDMA and amphetamines on striatal DAT
binding were assessed. MDMA users were compared to
polydrug using controls and the binding ratios in the striatum
were significantly increased (striatal binding ratios, increase
13 %, P = 0.045, ES = 2.92). However, comparing MDMA
users that used amphetamines less than 3 weeks before the
study toMDMA users, it was found that striatal binding ratios
were significantly decreased (striatal binding ratios, decrease
20 %, P = 0.007, ES = −4.09). This study concluded that use
of amphetamines, and not the use of MDMA, might induce
loss of nigrostriatal DA neurons. Because of the polydrug use
of many ecstasy users, it is hard to look specifically at the
effects of MDMA and they stressed the importance of the
inclusion of a proper control group.
Only one study (Tai et al. 2011) looked into decarboxylase
activity (using [18F]dopa PET) and found that there was a
significant increase in ex-MDMA users compared to drug-
naive controls, only in the putamen. However, the ex-
MDMA users were polydrug users and when comparing ex-
MDMA users to polydrug using controls, there was no signif-
icant effect anymore. This study stresses the importance of a
well-selected control group as well.
In short, the results on the DA system are quite consistent.
Most molecular imaging studies in humans did not find any
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significant effect of MDMA on the DA system. Further re-
search has to be conducted to draw definite conclusions
whether this system is affected in MDMA users.
Limitations
Several limitations of this review should be recognized. In this
review, we did not find imaging studies that assessed other
neurotransmitter systems than the 5-HT or DA system that
might be affected by MDMA. There is little imaging research
available on other receptors/transporters that may be influ-
enced by MDMA due to a lack of well-validated radiotracers
for every transporter/receptor of interest. Moreover, most of
the included studies used a very small number of subjects; the
number of subjects in animal studies was ranging from 1 to 26
animals and in human studies from 14 to 116 subjects.
Another limitation is the washout period used. A reasonable
period of abstinence of MDMA/ecstasy is necessary to ex-
clude direct pharmacological effects of MDMA on the neuro-
transmitter systems; this is of particular importance in studies
on the 5-HT and DA system. However, some studies in this
review used a minimal period of abstinence for ecstasy of only
1 week. Furthermore, the purity of ecstasy tablets varies and
the amount of MDMA in a tablet changed over the years;
consequently, there are limitations in comparing the results
of the human studies over time (Sherlock et al. 1999). Also,
not all studies were corrected for multiple comparisons, and




MDMA users are likely to be polydrug users. Several studies
attempted to look specifically at the effects of MDMA by
including polydrug using control groups. The study of Tai
et al. (2011) (Table 10) showed the importance of a polydrug
using control group, because there was no significant differ-
ence left in decarboxylase activity when the data of the
MDMA group were compared to the data obtained in the
polydrug control group. Different subgroups of polydrug
users were also analysed by two studies to investigate the
effects of some commonly used drugs in combination with
MDMA, e.g. cannabis, cocaine and hallucinogens, on the
binding of several transporters/receptors. This approach can
be useful, because it may assess the influence of those drugs
on the outcome of studies that included drug-naive controls
instead of polydrug controls.
First, the study of de Win et al. (2008b) assessed the
specific/independent neurotoxic effects of heavy ecstasy use
and contributions of amphetamine, cocaine and cannabis.
They concluded that use of cannabis and cocaine did not have
any significant effect on the effects of MDMA on SERT
binding as measured with [123I]β-CIT SPECT, comparing
MDMA users with polydrug using controls. In the second
study of Erritzoe et al. (2011), reductions were seen in the
cerebral SERT binding in MDMA-preferring users, but not
in hallucinogen-preferring users, and they concluded that not
hallucinogens, but MDMA alters the presynaptic 5-HT-ergic
transmitter system. Taken these studies into account, use of
cannabis, cocaine and hallucinogens may not influence the
effects of MDMA on the SERT significantly.
Age-of-first exposure
One study (Klomp et al. 2012) looked into the effects of age-
of-first exposure on SERT binding in humans and rats. In the
early-exposed group, they found a significant inverse relation-
ship between age-at-first ecstasy use and [123 I]β-CIT binding
ratios in the SERT-rich midbrain; however, in the late-exposed
group, no significant relationship was seen. They stated that,
particularly, the developing brain might be sensitive to the
potential neurotoxic effects of MDMA use. In early-exposed
rats and humans however, they did not find lower SERT bind-
ing ratios in the midbrain. A likely explanation may be that the
midbrain of rats is already matured very early in the matura-
tion process; consequently, the effects of MDMA are less
pronounced. These results suggest that in future studies, age-
of-first exposure should be taken into account. Animal studies
already concluded that the maturing brain is affected differ-
ently by the administration ofMDMA/ecstasy (Broening et al.
1994; Meyer and Ali 2002); however, no animal studies on
this topic were included. Only one human in vivo imaging
study passed our inclusion criteria; therefore, more research
has to be done to draw valid conclusions about what the role
of age-of-first exposure is on changes to neurotransmitter sys-
tems in humans.
Gender differences
Reneman et al. (2001a) reported about gender differences
in susceptibility to possible neurotoxic effects of MDMA
use. Several studies looked into this topic and came to
different conclusions. Buchert et al. (2004) confirmed
the association between sex and reduction of SERT
availability. However, de Win et al. (2008b) did not find
a gender effect on SERT availability. The only study that
looked into 5-HT synthesis reported on a decreased
[11C]AMT trapping in frontal regions in males, but not
in women (Booij et al. 2014). In this study, men seemed
to be more susceptible to the effects of polydrug use. In
conclusion, whether gender plays an important role in
susceptibility to the effects of MDMA use is not
completely clear and further research on this topic should
be undertaken.
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Alteration in receptor binding and neurotoxicity
The main outcome of imaging research is commonly
expressed in terms of increased or decreased receptor/
transporter binding; however, the cause of the alteration re-
mains unclear in these studies. There are at least four expla-
nations for the observed decrease in receptor/transporter bind-
ing: down-regulation and/or endocytosis of the receptor/trans-
porter, neuronal damage resulting in loss of receptors/
transporters which are expressed on this particular neuron,
decreased expression of protein levels of the receptor and
endogenous neurotransmitter release induced by the drug
which could reduce the binding of the radiotracer (e.g. admin-
istration of MDMA/ecstasy can induce 5-HT release, which
can lead to lower 5-HT2A receptor availability). In this regard,
it is of interest that a study by Quelch et al. (2012) showed a
significant reduction in the ability of the radioligand
[3H]DASB to bind to the SERTs that are located intracellularly
(as compared to binding on the SERT expressed on the cell
membrane) and they speculate that down-regulation could
(partly) explain the reductions in SERT binding in MDMA
studies with the radioligand [11C]DASB, since MDMA has
been shown to redistribute SERT into intracellular compart-
ments (Kivell et al. 2010). To distinguish between causes of
lower receptor/transporter binding, further research in animal
brains, e.g. using electron microscopy (to assess internaliza-
tion of receptor binding) or high-performance liquid chroma-
tography to assess neurotransmitter concentrations and deter-
mination of Bmax (number of binding sites) andKd (affinity for
the receptor), would be helpful.
Also, more translational research is necessary to examine
in which conditions lower SERT binding may reflect neuro-
toxicity. This is relevant since it is still debated whether ecsta-
sy use/administration is indeed neurotoxic. There are several
techniques developed that claim to measure neurotoxicity, e.g.
immunocytochemistry, immunohistochemistry, reactive
gliosis and silver staining. However, these techniques differ
in sensitivity and specificity and it can be questioned whether
t h ey a l l c an demons t r a t e 5 -HT neu ro tox i c i t y.
Immunocytochemistry can be used to look at the structural
and functional integrity of the assessed neurotransmitter sys-
tem. Immunohistochemistry can be used to assess 5-HT axon
degeneration; with this technique concentrations of 5-
hydroxyindoleacetic acid (5-HIAA), 5-HT and the SERT can
be measured (Battaglia et al. 1987; Commins et al. 1987).
Glial activation (reactive gliosis) is a response to all nervous
system injury, and silver staining is a direct way to stain
degenerating neurons (O’Callaghan and Sriram 2005).
However, there are several limitations of these techniques. It
is argued that immunohistochemistry should be validated by
other means, because the neurotransmitter levels could be un-
measurable due to pharmacological depletions, while the neu-
ron itself can be intact (Baumann et al. 2007; Chang and
Slikker Jr 1995). Silver staining is not selective for damage
to serotonergic axons but also measures loss of other types of
neurons. However, this technique is very useful for measuring
neuronal loss (Jensen et al. 1993; O’Callaghan and Miller
1993). In fact, no SPECT or PET tracer is available that can
directly assess serotonergic/dopaminergic toxicity or degener-
ation per se. So, until yet, whether or not a lowered receptor/
transporter binding as assessed by PET/SPECT studies in
humans represents neurotoxicity is still a matter of interpreta-
tion. Importantly, MDMA is not only used recreationally.
Some researchers proposed to treat patients with MDMA,
e.g. as a catalyst in psychotherapy for PTSD patients
(Amoroso 2015; Doblin et al. 2014; White 2014), which fur-
ther highlights the need to be able to assess whether or not the
use of ecstasy is neurotoxic to humans.
Recovery
Not only the causes, but also the duration of the effects of
MDMA/ecstasy on receptor/transporter binding is important
to be further explored. As mentioned earlier, a number of
studies have investigated the effect of the duration of ecstasy
abstinence on the SERT binding by examining the reversibil-
ity of the SERT binding in relation to period of abstinence
from MDMA use/administration. Scheffel et al. (1998) al-
ready showed in a baboon study that SERT binding was in-
creased from 40 days to 9months afterMDMA administration
in the pons, midbrain and hypothalamus, whereas it remained
decreased in cortical regions (pons: increase 35.7 %, mid-
brain: increase 95 %, hypothalamus: increase 168.5 %). In
human studies, similar results were found. Reneman et al.
(2001b) concluded that SERT binding of ex-MDMA users
that stopped using MDMA for more than a year was similar
to that binding of MDMA-naive controls. Moreover, Buchert
et al. (2004) found a significant positive correlation between
SERT binding and period of abstinence. Two years later, the
same research group found a significant increase over the
course of time of SERT binding of MDMA users and of
SERT binding in the thalamus of ex-MDMA users, respec-
tively (MDMA: P < 0.01; ex-MDMA: thalamus P = 0.006)
(Buchert et al. 2006). Selvaraj et al. (2009) further supported
the idea of SERT recovery; there was no difference in SERT
binding between former ecstasy users and drug-naive controls
after 1 year of abstinence. Moreover, Erritzoe et al. (2011)
concluded that the duration of abstinence was positively relat-
ed to SERT binding in pallidostriatum, amygdala and thala-
mus, but not in the neocortex. According to their data, recov-
ery of the pallidostriatal SERT binding takes 200 days. In
conclusion, there seems to be some evidence that there is a
recovery of SERT binding. If there is indeed recovery of
SERT binding over time, the relevant question is then whether
this recovery represents functionally intact 5-HT neurons. The
study of Reneman et al. (2001b) suggests that this may not be
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the case, because SERT binding in ex-MDMA users, who had
stopped using MDMA for more than 1 year, was similar to
control levels but demonstrated similar deficits on the RAVLT
memory test as current MDMA users. Indeed, a couple of
studies showed that even small doses of MDMA could lead
to cognitive impairments, e.g. in verbal memory, and these
impairments persist over time (Quednow et al. 2006; Schilt
et al. 2007). A review of Parrott (2013) confirms that different
cognitive functions can be affected by ecstasy use. There are
deficits found not only in retrospective and prospective mem-
ory but also in higher cognition, complex visual processing,
sleep architecture, sleep apnoea, pain, neurohormonal activity
and psychiatric status. Therefore, recovery of SERT binding
may reflect sprouting of 5-HT neurons or reduced endogenous
neurotransmitter release after 5-HT toxicity has occurred, in-
stead of recovery of the functional integrity of the 5-HT
neurons.
However, another study of Halpern et al. (2011) found little
evidence in ecstasy users for cognitive impairments. This
study was designed to minimize methodological limitations
and concluded that studies on cognitive function should be
interpreted with caution. If it is true that use of ecstasy does
not lead to persistent cognitive impairments, the recovery of
SERT binding may simply reflect normalization of the adap-
tation (e.g. down-regulation), which may occur initially after
MDMA use. In sum, several studies have shown that there is a
recovery in SERT binding after MDMA use/administration,
but it is not clear whether this is the result of recovery of the 5-
HT neurons or other causes. Future fundamental studies on
this topic are therefore recommended.
Implications for practice
Selection criteria for the inclusion of subjects are very impor-
tant for the quality of a given study. Research has shown that
regular ecstasy users are polydrug users, so controls have to be
matched on polydrug intake to rule out the effects of other
drugs. As mentioned earlier, some studies showed that results
were not significant anymore when polydrug-using controls
were used instead of controls without a history of other drugs.
The studies in this review used a great diversity of criteria to
select subjects.
To generalize findings from animal studies to the human
context, animal studies have to mimic the human context as
accurately as possible. Inmany animal studies on the effects of
MDMA, MDMAwas administered passively. However, ani-
mal studies in which MDMAwas self-administered may best
reflect the human situation. The effects found on SERT bind-
ing were less pronounced in studies which used MDMA self-
administration compared to studies which treated the animals
passively with MDMA (ES ranged from −0.72 to 5.82 in
SERT studies with self-administration and 0.69 to 20.03 in
other studies), although the accumulated lifetime intake was
higher in the studies with self-administering animals (97–
141 mg/kg lifetime intake compared to 40–80 mg/kg in other
studies). However, the number of animals used in these stud-
ies was relatively small; four MDMA self-administering mon-
keys and four controls were used in both studies.
Concluding remarks
In the present review, we examined the effects of the use/
administration of the drug ecstasy/MDMA on neurotransmit-
ter systems in human and animal brains through imaging stud-
ies. The results of imaging studies reveal consistently that
heavy use/administration of ecstasy/MDMA induces loss of
SERT binding; however, these studies cannot conclude defi-
nitely whether this reduction in binding represents 5-HT neu-
rotoxicity. The effects of MDMA/ecstasy on the 5-HT2A sys-
tem are not consistent, while in human, the DA system may
not be significantly affected. Some studies showed that use of
MDMA is correlated with deficits on several cognitive func-
tions; however, opinions remain divided on this topic.
Therefore, to come up with definite conclusions whether the
use of ecstasy is neurotoxic in humans, large translational
studies are still needed.
Current knowledge
– Heavy use/administration of MDMA decreases SERT
binding; however, after a certain period of time (40–
200 days), SERT binding recovers.
– In humans, MDMA does not seem to affect the DA
system.
– Use of cannabis, cocaine and hallucinogens does not
seem to influence the effects of MDMA on the SERT.
Remaining questions
– Is MDMA use able to induce detectable changes in 5-HT
synthesis? To validate this, supporting studies in small
laboratory animals may be performed with [11C]AMT
PET.
– Does a decline in SERT binding reflect neurotoxicity? It
may be relevant to perform more translational research.
– What is the cause and functional significance of SERT
binding recovery; sprouting, regeneration, recovery of ad-
aptation or endogenous neurotransmitter release? Future
fundamental studies on this topic are recommended.
– What are the causes of an increase or decrease in receptor
binding? Further research in animal brains could be done,
e.g. using high-performance liquid chromatography to
assess neurotransmitter concentrations and determination
of Bmax (number of binding sites) and Kd (affinity for the
receptor).
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– Does gender play an important role in susceptibility to
possible toxic effects of MDMA use?
– What are the effects of young ecstasy use? Results sug-
gest that there is an inverse relationship between age-at-
first ecstasy use and [123 I]β-CIT binding ratios in the
midbrain. However, only one study is performed on this
topic; therefore, more research has to be done to draw
valid conclusions.
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